Patents by Inventor Palash BHATTACHARYA

Palash BHATTACHARYA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF
    Publication number: 20230340413
    Abstract: This invention relates to chimeric polypeptides comprising OX40L and Jagged-1 polypeptides and fragments thereof and their uses for treatment of autoimmune diseases.
    Type: Application
    Filed: October 18, 2022
    Publication date: October 26, 2023
    Inventors: Bellur S. Prabhakar, Palash Bhattacharya, Prabhakaran Kumar
  • OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF
    Publication number: 20180320135
    Abstract: This invention relates to chimeric polypeptides comprising OX40L and Jagged-1 polypeptides and fragments thereof and their uses for treatment of autoimmune diseases.
    Type: Application
    Filed: November 3, 2016
    Publication date: November 8, 2018
    Inventors: Bellur S. Prabhakar, Palash Bhattacharya, Prabhakaran Kumar
  • Anti-CTLA4, anti-GLUT2 protein for the treatment of type 1 diabetes
    Patent number: 10072081
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 11, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • ANTI-CTLA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES
    Publication number: 20160137736
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Application
    Filed: November 17, 2015
    Publication date: May 19, 2016
    Applicant: The Board of Trustees of The University of Illinois
    Inventors: Bellur S. PRABHAKAR, Chenthamarakshan VASU, Palash BHATTACHARYA
  • Anti-CLTA4, anti-GLUT2 protein for the treatment of type 1 diabetes
    Patent number: 9221911
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 29, 2015
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • Anti-CLTA4, anti-GLUT2 protein for the treatment of type 1 diabetes
    Patent number: 8822649
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: September 2, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES
    Publication number: 20130323250
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Application
    Filed: July 17, 2013
    Publication date: December 5, 2013
    Inventors: Bellur S. PRABHAKAR, Chenthamarakshan VASU, Palash BHATTACHARYA
  • ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES
    Publication number: 20130236464
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 12, 2013
    Inventors: Bellur S. PRABHAKAR, Chenthamarakshan VASU, Palash BHATTACHARYA